Mutation of human lymphoblasts by methylnitrosourea

Area of Science:

• Molecular Biology
• Genetics
• Cell Biology

Background:

• Understanding gene mutation and expression is crucial in human cell lines.
• Methylnitrosourea (MNU) is a known mutagen used to induce genetic changes.
• Phenotypic lag can complicate the accurate assessment of mutation rates.

Purpose of the Study:

• To investigate the phenotypic lag in methylnitrosourea (MNU)-induced 6-thioguanine (6TG) resistance in human lymphoblastoid cells.
• To elucidate the underlying mechanisms contributing to the observed delay in mutant expression.
• To validate the accuracy of mutation fraction estimates in the presence of phenotypic lag.

Main Methods:

• Utilized a diploid human lymphoblastoid cell line.
• Induced mutations using methylnitrosourea (MNU).
• Assessed 6-thioguanine (6TG) resistance and employed reconstruction experiments to evaluate assay biases.

Main Results:

• A significant lag period of 8-12 days was observed before the appearance of new 6-thioguanine (6TG) resistant mutants.
• A stable maximum mutant fraction was attained after approximately two weeks.
• Preliminary data suggests the phenotypic lag is associated with the slow degradation of hypoxanthine-guanine phosphoribosyl transferase (HGPRT).
• Cellular resistance to 6TG requires very low levels of HGPRT (less than 0.2% of normal).

Conclusions:

• The phenotypic lag in MNU-induced 6TG resistance is a genuine genetic phenomenon, not an artifact of the assay.
• The slow degradation of HGPRT and the requirement for low HGPRT levels contribute to the observed lag.
• Assay conditions do not appear to introduce bias in the quantitative estimation of induced mutant fractions.